Purkiss Capital Advisors LLC Purchases Shares of 12,715 Johnson & Johnson (NYSE:JNJ)

Purkiss Capital Advisors LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 12,715 shares of the company’s stock, valued at approximately $1,839,000. Johnson & Johnson comprises approximately 1.6% of Purkiss Capital Advisors LLC’s portfolio, making the stock its 12th biggest position.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Knuff & Co LLC boosted its position in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares during the period. Vertex Planning Partners LLC boosted its position in Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management boosted its position in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC boosted its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after purchasing an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC boosted its position in Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after purchasing an additional 70 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on JNJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Guggenheim increased their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $167.08 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a fifty day moving average price of $151.33 and a two-hundred day moving average price of $156.08. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a market capitalization of $402.26 billion, a P/E ratio of 25.12, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.